Articles

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

University Hospital of Leipzig, Germany
Johannes-Wesling Academic Medical Center, University of Hannover Teaching Hospital, Minden, Germany
Charité – Universitätsmedizin Berlin, Germany
Department of Medicine I: Hematology and Oncology, University Hospital Freiburg, Germany
University of Perugia, Azienda Ospedaliera S. Maria, Terni, Italy
Department of Internal Medicine II, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Universidade Federal de Goiania, Goiás, Brazil
Miguel Servet University Hospital. IIS Aragon and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Zaragoza, Spain
St. Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada
Rabin Medical Center, Petah Tikva, Israel
Princess Margaret Cancer Centre, Toronto, ON, Canada
Novartis Pharma AG, Basel, Switzerland
Novartis Pharma AG, Basel, Switzerland
Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria, Italy
University of Florence, Italy
Vol. 101 No. 9 (2016): September, 2016 https://doi.org/10.3324/haematol.2016.143677